CompletedPhase 4NCT02458417
Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients
Studying Piebaldism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Netherlands Institute for Pigment Disorders
- Principal Investigator
- Albert Wolkerstorfer, MD, PhDNetherlands Institute for Pigment Disorders, Department of Dermatology, Academic Medical Center, University of Amsterdam
- Intervention
- ReCell(device)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2016
Study locations (1)
- Netherlands Institute for Pigment disorders, Amsterdam, Netherlands
Collaborators
Avita Medical
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02458417 on ClinicalTrials.gov